stonks4u
Log inSign up free
PLUR logo

PLUR Pluri Inc.

NASDAQ Global Market · Biotechnology · Healthcare

$1.70
+0.10 (+6.25%)

Pluri Inc., a biotechnology company established in 2001 and headquartered in Haifa, Israel, specializes in developing innovative placenta-derived cell therapies. Its core mission is to tackle a range of inflammatory conditions, muscle injuries, and hematological disorders. The company's therapeutic pipeline centers on placental expanded (PLX) cell technology. A key candidate, PLX-PAD, is in advanc…

Market Cap: $18.34Mpluri-biotech.com

Price

No data yet.

Signal Score (90d)

100
100
Aug 17Aug 17

Quote

Day Range
$1.61 – $1.72
52-Week Range
$1.45 – $5.68
Volume
$9.3K
Market Cap
$18.34M
50-Day Avg
$1.93
200-Day Avg
$2.98
Prev Close
$1.60
Open
$1.63

Valuation & Ratios

P/E Ratio
-1.39
EPS
$-3.56
P/B Ratio
-4.58
P/S Ratio
23.48
Debt/Equity
-4.98
Current Ratio
0.68
Dividend Yield
+0.0%
Gross Margin
+49.0%

Returns & Efficiency

Return on Equity
+330.1%
Return on Assets
-58.4%
FCF Yield
-63.2%
EV/EBITDA
-2.70

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$1.34M$-22.58M$-3.56
2024$326.0K$-20.89M$-3.99
2023$287.0K$-28.32M$-6.18
2022$234.0K$-41.24M$-10.24
2021$0.00$-49.87M$-14.19

Social Signal Score

50
5d
51
1 mentions
—
30d
50
1 mentions
—
60d
50
1 mentions
—
90d
50
1 mentions
—
news: 1

Earnings

Wed, Sep 23(in 5 weeks)

Consensus estimate $-0.66 per share

2of 5 quarters beat consensus

Typical surprise -9.2% (median, so one quarter with a near-zero estimate can't distort it)

  • Thu, May 14$-0.55 vs $-0.66beat
  • Thu, Feb 12$-0.71 vs $-0.65miss
  • Wed, Nov 12$-0.65 vs $-0.74beat
  • Wed, Sep 17$-2.62 vs $-0.65miss
  • Tue, May 13$-0.94 vs $-0.73miss

Estimates and results for PLUR via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Insider trading

Open-market buys and sells by PLUR officers and directors.

Bought
$12.5m

22 trades

Sold
$3.8m

12 trades

  • Manieu Alexandre Weinsteinbought
    director, 10 percent owner:·523,437 @ $4.61·$2.4m·Apr 28, 2025·filing
  • Manieu Alexandre Weinsteinbought
    director, 10 percent owner:·452,702 @ $4.61·$2.1m·Apr 28, 2025·filing
  • Aberman Zamisold
    director·2,000 @ $0.97·$2k·Dec 20, 2022·filing
  • Aberman Zamibought
    director·80,616 @ $1.80·$145k·Feb 10, 2022·filing
  • Clover Wolf Capital - Limited Partnershipsold
    10 percent owner·70,007 @ $3.72·$260k·May 28, 2021·filing
  • Clover Wolf Capital - Limited Partnershipsold
    10 percent owner·45,000 @ $3.72·$167k·May 28, 2021·filing
  • Clover Wolf Capital - Limited Partnershipsold
    10 percent owner·71,775 @ $3.69·$265k·May 27, 2021·filing
  • Clover Wolf Capital - Limited Partnershipsold
    10 percent owner·24,110 @ $3.69·$89k·May 27, 2021·filing

66 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.

Valuation

PLURhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·5h ago·Neutral

    Pluri's Ever After Foods Expands Cultivated-Protein Platform Through Fishway Acquisition and Strategic Investment Pluri's majority-owned food-tech company adds aquatic cell biology, animal-component-free media capabilities and a European scientific presence Pluri's majority-owned food-tech company adds aquatic cell biology, animal-component-free media capabilities and a European scientific presence

    View source ↗